{
    "nctId": "NCT04460911",
    "briefTitle": "Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.",
    "officialTitle": "Treatment Patterns And Clinical Outcomes Among Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (mBC) Receiving Palbociclib in Combination With Fulvestrant (PB+FUL) In The US Community Oncology Setting",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 317,
    "primaryOutcomeMeasure": "Time to Chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Documented diagnosis of HR+/HER2- mBC\n2. Initiated palbociclib + fulvestrant as first-line therapy in the metastatic setting and had at least 2 visits following the index date\n3. Received care at a US oncology site(s) utilizing the full EHR at time of treatment and data are available for research purposes\n\nExclusion Criteria:\n\n1. Enrollment in an interventional clinical trial during the study period\n2. Evidence of prior treatment with CDK4/6 inhibitors in the metastatic setting\n3. Receipt of treatment indicated for another primary cancer during the study period or history of another primary cancer documented within the US Oncology EHR.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}